ftInvstr
CIPLA · Healthcare ₹1381.0 -0.6% Mkt Cap ₹111463 Cr undervalued

CIPLA

Healthcare Drug Manufacturers - Specialty & Generic
₹1381.0
-0.6% today · 30d -6.31%
as of 2026-09-04
Price · Daily Candles
“Cipla's Profit Sinks 39% as DIIs Step Up, FIIs Pare Holdings”
Cipla's Q1 2027 net profit plunged 39.18% YoY to ₹786 Cr, alongside a 31.1% drop in operating profit, despite a modest 2.33% revenue increase. This dip contrasts with its 3-year net profit CAGR of 11.29%. The stock trades at a TTM P/E of 34.93, above its 52-week low of ₹1165.7 but still 13.23% off its 52-week high of ₹1673.
BULL CASE
+Cipla is considered undervalued with a 64% margin of safety, and an intrinsic value per share of ₹2380.03 against a current price of ₹1451.6.
+The company demonstrates strong profitability with a TTM profit margin of 12.01% and a ROCE of 17.0%.
+ML predictions indicate strong growth potential, with 1-year sales growth ranks of 0.878 (recent 2y), 0.858 (rolling 4y), and 0.801 (stable 7y).
+Domestic Institutional Investors (DIIs) increased their stake by 2.66% QoQ to 34.63% in the June 2026 quarter.
BEAR CASE
Net profit declined significantly by 39.18% YoY to ₹786 Cr in the quarter ending June 2026.
Operating profit also saw a sharp decline of 31.1% YoY, with the operating profit margin contracting by 9.08% to 19.14% in Q1 2027.
Foreign Institutional Investors (FIIs) reduced their holding by 2.35% QoQ, bringing their stake down to 20.21% by June 2026.
The stock is trading at a TTM P/E of 34.93, which is higher than peers like LUPIN (20.4) and ZYDUSLIFE (22.03).
⟳ What Changed
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹7119 Cr
+2.33% YoY
NET PROFIT
₹786 Cr
-39.18% YoY
OPM
19.14%
-9.08pp YoY
EPS
₹9.77
PE 34.93
Intrinsic value · DCF ₹2221.57 · Margin of safety +60.9% (undervalued) · FCF yield 2.1%
◇ Sector Position
Cipla trades at a TTM P/E of 34.93 with a ROCE of 17.0%, positioning it above peers like LUPIN (P/E 20.4, ROCE 27.37%) but below DIVISLAB (P/E 81.85, ROCE 21.47%) in the Drug Manufacturers sector.
PEERPEROCE %
CIPLA34.9317.0
SUNPHARMA38.7522.46
DIVISLAB81.8521.47
ZYDUSLIFE22.0325.71
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
54
SCORE / 100
Overall
6-axis composite of the sections below.
Performance NEUTRAL 40
Valuation FAIR 40
Growth MUTED 48
Profitability HIGH 78
Technicals WEAK 38
Risk LOW 80
Key Stats
TTM PE
34.93
P/B
3.42
52W HIGH
₹1673.0
OFF HIGH
-17.45%
DIV YIELD
0.89%
MKT CAP
₹111463 Cr
◉ Active Signals
MACDBearish-5.246
RSI(14)Bearish32.94
Street Consensus
36 analysts
₹1509.08
mean target
Low ₹1170.0Now ₹1381.0High ₹1768.0
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold CIPLA and at what entry.

Sign up freeSign in